

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2026 first extraordinary general meeting (the “**EGM**”) of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”) will be held at the Conference Room on the 6th Floor of Headquarters Building, 38 Chuangye North Road, Jinwan District, Zhuhai, Guangdong Province, China at 2:00 p.m. on Thursday, 24 September 2026 for the purposes of considering and, if thought fit, passing the following resolution.

ORDINARY RESOLUTION

1. To consider and approve the 2026 Special Interim Dividend to reward Shareholders.

Notes:

1. All resolutions at the EGM will be taken by poll pursuant to The Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”). The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.livzon.com.cn) in accordance with the Hong Kong Listing Rules.
2. The record date for determining the qualification of the holders of the shares of the Company (“**Shareholder(s)**”) to attend and vote at the EGM will be Friday, 18 September 2026. In order to qualify as Shareholders to attend and vote at the EGM, the holders of H shares of the Company (the “**H Shareholders**”) who are not registered must lodge all transfers of shares accompanied by the relevant share certificates with the H Share Registrar of the Company, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Friday, 18 September 2026.
3. The 2026 Special Interim Dividend to reward Shareholders will be submitted to the EGM for consideration. If the proposal is approved at the EGM, the Special Interim Dividend will be distributed to (i) all holders of A Shares of the Company registered on the register of members with the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited after the close of trading on the Shenzhen Stock Exchange on the afternoon of Tuesday, 13 October 2026; and (ii) the holders whose names appear on the register of members for H Shares of the Company at the close of business on Thursday, 15 October 2026.

The aforementioned Special Interim Dividend will be denominated in RMB and will be distributed in RMB to A Shareholders and in HK\$ to H Shareholders. The exchange rate for the payment of the dividend in HK\$ will be calculated based on the central parity rate of RMB against HK\$ announced by the People's Bank of China on the date on which this Special Interim Dividend is considered and approved at the EGM (24 September 2026).

The record date for determining the qualification of the H Shareholders for the proposed distribution of the Special Interim Dividend will be Thursday, 15 October 2026. In order to qualify for the Special Interim Dividend, H Shareholders whose transfer documents are not registered must lodge all transfer documents of shares accompanied by the relevant share certificates with the Company's H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on Thursday, 15 October 2026.

For A Shareholders, the record date, payment methods and time for Special Interim Dividend will be announced separately.

Pursuant to the provisions of the Announcement on Matters Relating to the Individual Income Tax Policies on Dividends and Bonuses for Overseas Individuals (Announcement of Ministry of Finance and State Administration of Taxation 2026 No. 27), dividend and bonus income obtained by overseas individuals from foreign invested enterprises shall be subject to individual income tax under "interests, dividend and bonus income" at an applicable tax rate of 20%. When a foreign invested enterprise distributes dividends and bonuses to overseas individuals, it shall withhold and pay tax, and declare and pay tax within 15 days of the month following the payment of the income. Where a foreign invested enterprise fails to withhold tax, the overseas individual who receives dividends and bonuses shall pay the tax on or before 30 June of the year following the receipt of the income. Where the tax authority issues a notice requiring payment within a prescribed time limit, the overseas individual shall pay the tax in accordance with such time limit. As the Company is a foreign invested enterprise, the Company is obliged to withhold and pay 20% individual income tax on behalf of overseas individual shareholders whose names appear on the register of members for H Shares of the Company when the Company distributes dividends.

According to the Corporate Income Tax Law of the People's Republic of China (《中華人民共和國企業所得稅法》), and its implementation regulations, as well as the Notice of the State Taxation Administration on Issues Relevant to the Withholding and Paying of Corporate Income Tax on Dividends Paid by PRC Resident Enterprises to Offshore Non-resident Enterprise Shareholders of H Shares (Guo Shui Han [2008] No. 897) (《國家稅務總局關於中國居民企業向境外H股非居民企業股東派發股息代扣代繳企業所得稅有關問題的通知》(國稅函[2008]897號)), with effect from 1 January 2008, when a PRC resident enterprise pays dividends for 2008 or any year thereafter to overseas non-resident enterprise shareholders of H Shares, it shall withhold and pay corporate income tax thereon at a uniform rate of 10%. Therefore, the Company is required to withhold and pay corporate income tax at the rate of 10% when distributing the Special Interim Dividend to non-resident enterprise shareholders whose names appear on the register of members for H Shares on the record date.

According to the relevant provisions of the Notice of the Ministry of Finance, the State Taxation Administration and the China Securities Regulatory Commission on the Tax Policies Related to the Pilot Programme of the Shanghai-Hong Kong Stock Connect (Cai Shui [2014] No. 81) (《財政部國家稅務總局證監會關於滬港股票市場交易互聯互通機制試點有關稅收政策的通知》(財稅[2014]81號)), the Notice on the Tax Policies Related to the Pilot Programme of the Shenzhen-Hong Kong Stock Connect (Cai Shui [2016] No. 127) (《關於深港股票市場交易互聯互通機制試點有關稅收政策的通知》(財稅[2016]127號)), and the Announcement on Continuing the Implementation of the Individual Income Tax Policies Concerning the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect and the Mutual Recognition of Funds between Chinese Mainland and Hong Kong (《關於延續實施滬港、深港股票市場交易互聯互通機制和內地與香港基金互認有關個人所得稅政策的公告》) (Announcement No. 23 of 2023 issued by the Ministry of Finance, the State Taxation Administration and the China Securities Regulatory Commission, effective until 31 December 2027): (i) domestic individual investors and domestic securities investment funds: For dividends and bonuses received from investing in H Shares listed on the Hong Kong Stock Exchange through Southbound Trading Link, individual income tax shall be withheld and paid by the Company at the rate of 20%; (ii) domestic enterprise investors: The Company will not withhold and pay income tax for such dividends, and the tax payable shall be declared and paid by the enterprise investors themselves.

Shareholders are advised to consult their tax advisers regarding PRC, Hong Kong and other tax implications arising from their holding and disposal of H Shares of the Company.

4. Any Shareholder entitled to attend and vote at the EGM is entitled to appoint one or more persons as his/her/its proxy to attend and vote in his/her/its stead. A proxy need not be a Shareholder of the Company. If more than one proxy is so appointed, the appointment shall specify the number and class of shares in respect of which each such proxy is so appointed.
5. A Shareholder shall attend the EGM by his/her/its proxy duly authorised in writing. The instrument appointing a proxy must be signed by the Shareholder(s) or his/her/its attorney duly authorised in writing. Where the Shareholder is a legal person, the proxy form shall be executed under its common seal or under the hand of its director or a legal representative or an attorney duly authorised. If the proxy form is signed by the attorney of the Shareholder, the power of attorney or other documents of authorisation must be notarised. To be valid, the holders of A shares of the Company must lodge the proxy form and the notarised power of attorney or other documents of authorisation (if any) with the Secretariat of the Board of the Company at Headquarters Building, 38 Chuangye North Road, Jinwan District, Zhuhai, Guangdong Province, China (postal code: 519090) not less than 24 hours before the holding of the EGM. To be valid, the H Shareholders must lodge the proxy form with the H Share Registrar of the Company, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 24 hours before the holding of the EGM. Completion and return of the proxy form will not preclude Shareholders from attending and voting at the EGM or any adjournment thereof in person, and in such event, the proxy form shall be deemed to be revoked.
6. Contact details of the Secretariat of the Board are as follows:

Address:	Office of the Secretariat of the Board, Livzon Pharmaceutical Group Inc., Headquarters Building, 38 Chuangye North Road, Jinwan District, Zhuhai, Guangdong Province, China
Postal code:	519090
Contact person:	Ms. Xia Yu
Telephone:	(86) (756) 8135023
Fax:	(86) (756) 8891070
7. H Shareholders or their proxies shall produce their identity proof when attending the EGM.
8. The EGM is expected to last for one hour. Shareholders (in person or by proxy) who attend the EGM should be responsible for their own travelling, lodging and the related costs.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc.*
Liu Ning
Company Secretary

Zhuhai, China
8 September 2026

As at the date of this notice, the executive directors of the Company are Mr. Liu Daping (President) and Mr. Tang Yanggang (Vice Chairman); the non-executive directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee representative director of the Company is Ms. Ran Yongmei; and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

* For identification purpose only